GlassScriptPhysician profile
Gordon B Waters
NPI 1730109414
$4,490.77
in general payments reported to CMS, 2019-2025
42 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $690 · 2021: $930 · 2022: $35.00 · 2024: $909 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $549.18 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $488.70 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $351.18 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $303.36 | 2021-2025 | |
| Pfizer INC. | $276.33 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.08 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $214.32 | 2020-2025 | Veozah |
| Glaxosmithkline, LLC. | $211.61 | 2020-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $184.10 | 2024-2025 | |
| Antares Pharma, INC. | $168.10 | 2020-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.70 | 2019-2024 | Jardiance, Synjardy |
| Indivior INC. | $128.53 | 2019-2025 | Sublocade |
| Lilly USA, LLC | $114.47 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.32 | 2025 | Caplyta |
| Genentech USA, INC. | $97.13 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.